Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor in endovascular stroke treatment with emergent carotid artery stenting (CANCAS)
2025-521564-35-00Phase 2Authorised
- Sponsor
- Medical University of Graz
- Start
- Oct 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cangrelor in ischemic stroke and carotid atheroma (CAS), sponsored by Medical University of Graz. Primary endpoint: Carotid artery stent patency at 24 (±6) hours after stenting. Planned start Oct 2025; status: authorised.
02
Drugs
cangrelor
03
Conditions
ischemic strokecarotid atheroma (CAS)
Beyond the preview
Go deeper on 2025-521564-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521564-35-00.